Sleep apnea happens when breathing stops and starts many times during sleep because the airway is blocked or the brain stops sending signals to breathe. This interrupts sleep quality and reduces oxygen delivery to the body. Usually, doctors diagnose sleep apnea using an overnight test called polysomnography (PSG) done in special sleep labs. PSG is the standard test, but it has problems:
These issues cause many cases to be missed or diagnosed late, which harms patient health and adds pressure to healthcare systems.
Companies and doctors in the U.S. are now using artificial intelligence (AI) and remote patient monitoring (RPM) to improve how sleep apnea is found and treated. These new tools let patients take tests at home and get continuous monitoring. This can help find sleep apnea earlier and personalize care.
For example, the Chicago ENT/Chicago Sleep Center (CENT/CSC) quickly adopted AI-powered sleep testing. They switched over 75% of home tests from older devices to new photoplethysmography (PPG) devices in just three months. These PPG devices cost much less—$150 instead of $2,000—making testing easier to get for more people.
EnsoSleep PPG uses pulse oximeter data analyzed by AI. Patients can test at home without spending the night in a lab. Results come back faster, so doctors can make decisions sooner. This AI tool helps reduce wait times and lower costs from delayed diagnosis.
Connected CPAP machines and wearable devices are important for tracking how well patients follow their sleep therapy. Devices like ResMed’s AirSense 11 and AirMini collect real-time data on apnea episodes, use time, and sleep quality. They connect to apps like myAir that give patients daily sleep scores and tips to keep up their therapy.
Platforms such as Apnolab gather data from many CPAP brands including ResMed, Philips, and Lowenstein. This lets doctors see all patient information in one place, no matter the device brand. This helps them monitor patients and adjust treatment better.
Wearable devices like the Apple Watch use motion and pulse sensors to spot early signs of sleep apnea. Though they do not diagnose, they can warn patients to get a full checkup. Non-contact monitors like the Withings Sleep Analyzer use sensors under the mattress to track sleep and breathing without touching the body. These devices make testing more comfortable for patients.
RPM gathers health data from patients outside the clinic over multiple nights, giving a fuller picture of sleep health. This is better than a single-night test because sleep and breathing can change nightly.
Companies such as Impilo and Wesper use real-time data with small, wireless sensors that patients wear at home. Wesper’s patches track key factors like oxygen levels, airflow, and sleep position without bothering the patient. Impilo’s platform collects this data and shares it with doctors quickly. This helps doctors notice problems early, adjust treatments, and watch patient progress without many office visits.
These systems follow HIPAA rules, which keep patient information private and secure. For healthcare providers, using RPM and home tests can lower workloads, reduce delays, and help more people who have trouble with traditional testing.
AI helps more than just diagnosing—it also makes administrative work easier. Automated scoring systems can analyze sleep tests and create reports without human error. This speeds up report delivery and lets staff focus more on patients.
AI can predict if patients will follow their CPAP treatment by looking at factors like age, other diseases, and past device use. Early warnings let healthcare teams offer education or alternatives sooner, improving results.
AI systems can also automate scheduling appointments, sending devices, and giving instructions. This reduces the work for managers and staff in busy practices.
This fits well with the goals of medical practice owners and IT teams in the U.S. They want to save time and money while keeping care quality high as patient numbers grow.
Many people in the U.S. have sleep apnea but do not know it. The problem is growing with more obesity and older adults. Blackstone Medical Services (BMS) works with EnsoData to close this gap by mixing AI with home testing.
BMS, a Medicare-approved testing center, uses EnsoSleep PPG to offer affordable, easy testing for doctors across the country. Patients can take multi-night home sleep studies quickly, and results come back in days. This speeds up diagnosis and lets doctors manage care better, lowering risks from untreated sleep apnea.
According to Vick Tipnes, CEO of BMS, this solution makes fast and accurate tests possible nationwide. Dr. Justin Mortara, CEO of EnsoData, says AI technology helps reach more patients who might otherwise go undiagnosed.
Healthcare leaders, owners, and IT managers in sleep care can see many benefits from AI and remote monitoring:
Still, there are challenges. Providers must fit AI tools into existing electronic health record (EHR) systems and train staff to trust and use AI results well. Reimbursement rules for remote tests can be tricky. Also, AI systems must use diverse patient data to avoid bias and ensure fair care.
AI and remote monitoring are helping make sleep apnea care easier to get, faster, and more focused on patients’ needs. Medical practices in the United States can use these tools to give better care, save money, and meet the need for diagnosing and treating sleep problems.
The main focus is to enhance patient outcomes and reduce overhead costs by implementing EnsoSleep PPG, an AI-powered sleep diagnostic tool.
EnsoSleep PPG is an FDA-cleared, AI-powered software as a medical device (SaMD) that utilizes pulse oximeter data for streamlined home sleep testing.
They transitioned over 75% of their home testing from flow-based devices to more affordable PPG-based devices within three months.
The cost per device has been reduced from $2,000 to $150, significantly lowering the expenses associated with sleep diagnostics.
They began using EnsoSleep PPG in August 2024.
The benefits include faster patient outcomes, reduced equipment costs, and more efficient testing processes.
It leverages data from pulse oximeters to assess patient conditions related to sleep.
The adoption occurred rapidly, with a significant shift in home testing methods happening in just three months.
The case study aims to illustrate the efficient adoption process of EnsoSleep PPG and the associated benefits.
EnsoData has also introduced AI-driven remote physiological monitoring and added new channels to enhance home sleep apnea testing.